The Center for Biosimilars® recaps the top 5 articles for the week of June 4, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 4.
Number 5: Mylan and its partner Biocon received a Complete Response Letter from the FDA for their follow-on insulin glargine referencing Lantus.
Number 4: Celltrion has reported positive results of a study of a subcutaneous formulation of its biosimilar infliximab, Inflectra, in patients with Crohn disease.
Number 3: The FDA published new draft guidance that clarifies the types of formal meetings that biosimilar applicants can hold with the agency.
Number 2: During the 2018 American Society of Clinical Oncology Annual Meeting, researchers presented on new directions in anticancer and supportive care biosimilars.
Number 1: The FDA has approved its first pegfilgrastim biosimilar, Fulphila, referencing Neulasta.
Finally, last week, our e-newsletter asked whether you that US payers should encourage greater use of biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).